Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.87 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | PPARD | Q03181 | 5/20 | 0.63 |
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | F7 | P08709 | 5/20 | 0.63 |
| ▸ | F3 | P13726 | 5/20 | 0.63 |
| ▸ | FABP4 | P15090 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2508939 | 1.00 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL29809746 | 1.00 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL15335332 | 1.00 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL3735713 | 0.99 | MAPT (0.85) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL3735715 | 0.99 | MAPT (0.85) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL21214014 | 0.99 | MAPT (0.85) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL3737730 | 0.95 | MAPT (0.79) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL15335272 | 0.95 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL15377389 | 0.95 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD | |
| SCHEMBL15323230 | 0.95 | MAPT (0.87) | MAPTALOX5PPARGALDH1A1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582649-B2 | Compositions and methods for hair follicle regeneration | WASHINGTON UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-20250171740-A1 | METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-05-29 | — | — | US | claimed |
| CN-119069037-B | Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model | 中国中医科学院医学实验中心 | 2025-02-14 | — | — | CN | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| CN-119069037-A | Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model | 中国中医科学院医学实验中心 | 2024-12-03 | — | — | CN | claimed |
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | claimed |
| CN-117761179-A | Research method for predicting postpartum life intervention effect of pregnant diabetes puerpera by using metabolite 5,6-EET | 中山大学附属第一医院 | 2024-03-26 | — | — | CN | claimed |
| EP-4329742-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-03-06 | — | — | EP | claimed |
| US-20230277528-A1 | COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION | WASHINGTON UNIVERSITY (US) | 2023-09-07 | — | — | US | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| EP-3383182-B1 | METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-108601356-B | Method for producing functional hematopoietic stem cells | 布里格姆妇女医院 | 2023-01-10 | — | — | CN | claimed |
| WO-2022232633-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-11-03 | — | — | WO | claimed |
| US-7214495-B2 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-08 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| CN-121899422-A | Application of 5,6-EET as predictive marker of lung metastasis of triple negative breast cancer | 南开大学 | 2026-04-21 | — | — | CN | disclosed |
| US-7214495-B2 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20050089866-A1 | Novel screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1479768-A1 | NOVEL SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | MAPT 3885/4885ALOX5 4344/4885PPARG 1667/4885 |
| US-20230277528-A1 | COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION | TRPV4, TRPC4, S100A4 | MAPT 3546/4885ALOX5 732/4885PPARG 365/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | MAPT 2450/4885ALOX5 23/4885PPARG 11/4885 |
| US-12582649-B2 | Compositions and methods for hair follicle regeneration | TRPV4, TRPV6, TRPM4 | MAPT 2276/4885ALOX5 2726/4885PPARG 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.